

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

JOHNSON & JOHNSON
Form 8-K
December 04, 2002

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 4,
2002

JOHNSON & JOHNSON

(Exact name of registrant as specified in its charter)

| | | |
|--|----------------------------|---|
| New Jersey | 1-3215 | 22-1024240 |
| (State or other jurisdiction of incorporation) | Commission File Number) | (I.R.S. Employer Identification No.) |

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933
(Address of principal executive offices) (zip code)

Registrant's telephone number including area code: (732) 524-0400
Item 5. Other Events.

On December 2, 2002, Johnson & Johnson ("J&J") issued the
attached press release statement on the change in European
labeling for EPREX/ERYPO (epoetin alfa) that is filed as Exhibit
99.15 to this Form 8K.

Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.

(c) Exhibits

| Exhibit No. | Description of Exhibit |
|-------------|---------------------------------------|
| 99.15 | Press Release dated December 2, 2002. |

SIGNATURE

Edgar Filing: JOHNSON & JOHNSON - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JOHNSON & JOHNSON

Date: December 4, 2002

By: /s/ Stephen J. Cosgrove
Stephen J. Cosgrove
Chief Accounting Officer